Jeffrey J. Jones

4.2k total citations · 1 hit paper
32 papers, 1.9k citations indexed

About

Jeffrey J. Jones is a scholar working on Molecular Biology, Genetics and Spectroscopy. According to data from OpenAlex, Jeffrey J. Jones has authored 32 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Genetics and 10 papers in Spectroscopy. Recurrent topics in Jeffrey J. Jones's work include Chronic Lymphocytic Leukemia Research (11 papers), Mass Spectrometry Techniques and Applications (10 papers) and Bacterial Identification and Susceptibility Testing (5 papers). Jeffrey J. Jones is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Mass Spectrometry Techniques and Applications (10 papers) and Bacterial Identification and Susceptibility Testing (5 papers). Jeffrey J. Jones collaborates with scholars based in United States, Germany and Poland. Jeffrey J. Jones's co-authors include Joseph M. Flynn, John C. Byrd, Amy J. Johnson, Amber Gordon, Charles L. Wilkins, Kristie A. Blum, Xiaoli Zhang, Sarah E. M. Herman, Joseph J. Buggy and Erin Hertlein and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jeffrey J. Jones

31 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

2011 607 citations Sarah E. M. Herman, Amber Gordon et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey J. Jones United States	19	1.1k	814	746	456	339	32	1.9k
Mint Sirisawad United States	17	956 0.9×	1.3k 1.5×	767 1.0×	416 0.9×	334 1.0×	38	2.4k
Lily L. Remsing Rix United States	19	358 0.3×	902 1.1×	71 0.1×	149 0.3×	465 1.4×	28	1.8k
Matthew R. Janes United States	15	247 0.2×	2.2k 2.7×	195 0.3×	285 0.6×	243 0.7×	26	2.7k
Lisa Roberts United States	9	223 0.2×	1.4k 1.7×	186 0.2×	248 0.5×	205 0.6×	20	1.9k
Jessica Adickes United States	4	204 0.2×	1.4k 1.7×	191 0.3×	248 0.5×	200 0.6×	4	1.9k
Yi Hua Qiu United States	18	163 0.2×	974 1.2×	103 0.1×	163 0.4×	633 1.9×	38	1.4k
Pietro Taverna United States	27	308 0.3×	1.8k 2.2×	455 0.6×	286 0.6×	373 1.1×	90	2.5k
Haleh Saber United States	13	243 0.2×	624 0.8×	130 0.2×	213 0.5×	276 0.8×	20	1.6k
Nathan T. Ihle United States	15	216 0.2×	1.2k 1.5×	213 0.3×	96 0.2×	43 0.1×	23	1.5k
Christian R. Geest Netherlands	10	454 0.4×	476 0.6×	300 0.4×	349 0.8×	241 0.7×	16	1.1k

Countries citing papers authored by Jeffrey J. Jones

Since Specialization

Citations

This map shows the geographic impact of Jeffrey J. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey J. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey J. Jones more than expected).

Fields of papers citing papers by Jeffrey J. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey J. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey J. Jones. The network helps show where Jeffrey J. Jones may publish in the future.

Co-authorship network of co-authors of Jeffrey J. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey J. Jones. A scholar is included among the top collaborators of Jeffrey J. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey J. Jones. Jeffrey J. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Iijima, Hirotaka, Gabrielle Gilmer, Kai Wang, et al.. (2023). Age-related matrix stiffening epigenetically regulates α-Klotho expression and compromises chondrocyte integrity. Nature Communications. 14(1). 18–18. 61 indexed citations

Jones, Jeffrey J., et al.. (2022). System-wide analyses reveal essential roles of N-terminal protein modification in bacterial membrane integrity. iScience. 25(8). 104756–104756. 6 indexed citations

Zhang, Tianyi, Xiang Ma, Amirhossein Mafi, et al.. (2021). A proteome-wide map of 20(S)-hydroxycholesterol interactors in cell membranes. Nature Chemical Biology. 17(12). 1271–1280. 40 indexed citations

Thangavadivel, Shanmugapriya, Qiuhong Zhao, Narendranath Epperla, et al.. (2020). Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clinical Cancer Research. 26(23). 6187–6195. 3 indexed citations

Kochel, Christina M., Jeffrey J. Jones, Megan J. Welch, et al.. (2020). 698 Targeting HLA-G-mediated immunosuppression with a first-in-class antagonist antibody. SHILAP Revista de lepidopterología. A419.2–A420.

Jones, Jeffrey J., Bruce E. Wilcox, Ryan W. Benz, et al.. (2016). A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass Spectrometry. Clinical Colorectal Cancer. 15(2). 186–194.e13. 27 indexed citations

Byrd, John C., Jeffrey J. Jones, Jennifer A. Woyach, Amy J. Johnson, & Joseph M. Flynn. (2014). Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician. Journal of Clinical Oncology. 32(27). 3039–3047. 83 indexed citations

Stephens, Deborah M., Amy S. Ruppert, Kami J. Maddocks, et al.. (2013). Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leukemia Research. 37(10). 1195–1199. 24 indexed citations

Wei, Jie, Jeffrey J. Jones, Jing Kang, et al.. (2011). RNA-Induced Silencing Complex-Bound Small Interfering RNA Is a Determinant of RNA Interference-Mediated Gene Silencing in Mice. Molecular Pharmacology. 79(6). 953–963. 40 indexed citations

10.

Herman, Sarah E. M., Amber Gordon, Erin Hertlein, et al.. (2011). Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 117(23). 6287–6296. 607 indexed citations breakdown →

11.

Jones, Jeffrey J.. (2010). Countering Islamic radicalization and Al Shabaab recruitment within the ethnic Somali population of the United States : an argument for applying best practices for stemming youth gang recruitment and initiation. Calhoun: The Naval Postgraduate School Institutional Archive (Naval Postgraduate School). 1 indexed citations

12.

Blum, Kristie A., Zhongfa Liu, David Lucas, et al.. (2010). Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: dose‐limiting myelosuppression without evidence of DNA hypomethylation. British Journal of Haematology. 150(2). 189–195. 57 indexed citations

13.

Kenski, Denise M., Jing Li, Aarron Willingham, et al.. (2009). Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5′-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Research. 38(2). 660–671. 67 indexed citations

14.

Borgmann, Sabine, Karin Flick, Jeffrey J. Jones, et al.. (2008). Lipid and Phospholipid Profiling of Biological Samples Using MALDI Fourier Transform Mass Spectrometry. Lipids. 44(4). 367–371. 8 indexed citations

15.

Jones, Jeffrey J., et al.. (2007). SNS-595 potentiates the in vivo antitumor activity of carboplatin, cisplatin, and gemcitabine in solid tumor xenografts.. Molecular Cancer Therapeutics. 6. 3 indexed citations

16.

Reddy, Mamatha, et al.. (2007). SNS-032 has potent antitumor activity in vivo against human leukemia and multiple myeloma xenografts. Molecular Cancer Therapeutics. 6. 2 indexed citations

17.

Jones, Jeffrey J., Sabine Borgmann, Charles L. Wilkins, & Richard M. O’Brien. (2006). Characterizing the Phospholipid Profiles in Mammalian Tissues by MALDI FTMS. Analytical Chemistry. 78(9). 3062–3071. 46 indexed citations

18.

Jones, Jeffrey J., Charles L. Wilkins, Yingjie Cai, et al.. (2005). Real‐Time Monitoring of Recombinant Bacterial Proteins by Mass Spectrometry. Biotechnology Progress. 21(6). 1754–1758. 9 indexed citations

19.

Jones, Jeffrey J., et al.. (2005). A comprehensive and comparative analysis for MALDI FTMS lipid and phospholipid profiles from biological samples. Computational Biology and Chemistry. 29(4). 294–302. 22 indexed citations

20.

Jones, Jeffrey J., et al.. (2005). Ionic liquid matrix-induced metastable decay of peptides and oligonucleotides and stabilization of phospholipids in MALDI FTMS analyses. Journal of the American Society for Mass Spectrometry. 16(12). 2000–2008. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact